Search results
Results from the WOW.Com Content Network
Medroxyprogesterone acetate (MPA), also known as depot medroxyprogesterone acetate (DMPA) in injectable form and sold under the brand name Depo-Provera among others, is a hormonal medication of the progestin type. [10] [4] It is used as a method of birth control and as a part of menopausal hormone therapy.
Progestogens that have been studied for potential use as POICs but were never marketed as such include the progesterone derivatives algestone acetophenide (dihydroxyprogesterone acetophenide) (100 mg/month), chlormadinone acetate (250 mg/3 months), hydroxyprogesterone caproate (250–500 mg/month), gestonorone caproate (2.5–200 mg/1–2 ...
Progestogens have been found to maximally suppress circulating testosterone levels in men by up to 70 to 80% at sufficiently high doses. [ 219 ] [ 220 ] This is notably less than that achieved by GnRH analogues , which can effectively abolish gonadal production of testosterone and suppress circulating testosterone levels by as much as 95%. [ 221 ]
Medroxyprogesterone, also known as 6α-methyl-17α-hydroxyprogesterone or as 6α-methyl-17α-hydroxypregn-4-en-3,20-dione, is a synthetic pregnane steroid and a derivative of progesterone. [ 2 ] [ 3 ] It is specifically a derivative of 17α-hydroxyprogesterone with a methyl group at the C6α position.
In the past, medrogestone was used in the treatment of endometrial cancer and in some regimens for breast cancer, and, in men, for benign prostatic hyperplasia. It still finds use in the treatment of amenorrhea [ 14 ] and as the progestin component in certain forms of menopausal hormone therapy .
The new progestational agent was [6α-methyl-17α-hydroxyprogesterone acetate] or [medroxyprogesterone acetate], which Upjohn has trademarked Provera. It has proved to be the most potent progestational drug yet uncovered — hundreds of times more active orally than progesterone and, weight for weight, some fifty times more active by ...
Use of combined oral contraceptive pills, however, varies widely by country, [18] age, education, and marital status. For example, one third of women aged 16–49 in the United Kingdom use either the combined pill or progestogen-only pill (POP), [ 19 ] [ 20 ] compared with less than 3% of women in Japan (as of 1950–2014).
Depo Provera, the shot: 4 (1 in 25) 0.2 (1 in 500) Progestogen: Injection: 12 weeks: Testosterone injection for male (unapproved, experimental method) [39] Testosterone Undecanoate: 6.1 (1 in 16) 1.1 (1 in 91) Testosterone: Intramuscular Injection: Every 4 weeks: 1999 cervical cap and spermicide (replaced by second generation in 2003) [40] FemCap